Stock Market News
JPMorgan upgrades Spectris to 'overweight', expects strong second half performance
A lacklustre share price performance in 2017 for precision instruments supplier Spectris, while partly driven by a lack of earnings growth relative to the sector, was mainly due to the sluggish organic growth seen from the firm early in the year.
However, with growth picking up throughout the second half of the year, analysts at JPMorgan Cazenove tapped the group as a solid candidate to have ended the year on a positive note and forecast stronger profit growth going forward, which led the analysts to raise their recommendation for the shares from 'neutral' to 'overweight'.
JPMorgan said the benefits of cost-cutting, organic growth of at least 2.5% and boosts from acquisitions throughout the year should help improve operating profit by around 25% between 2017 and 2019.
Spectris was forecast to post flat operating profits for the year, despite further revenue growth, but come twelve months later, JP Morgan estimated operating profits to move ahead no less than 14% and predicted operating profit growth of 12% in 2019.
The analysts said, "Over the past 18 months, Spectris has completed five acquisitions, the most significant of which were Millbrook and Concept Life Science which deliver testing services to the auto and pharma industries, respectively. We expect the annual number of new model launches by the auto industry in Europe to rise by almost 50% between 2017 and 2020."
"Overall, we expect this to trigger a re-rating of the group. With the shares trading at a discount to the sector and with 16% upside potential our revised Dec-18 price target of 2,900p (was 2,800p)," they concluded.
As of 1430 GMT, shares had grown 2.42% to 2,544.00p.
However, with growth picking up throughout the second half of the year, analysts at JPMorgan Cazenove tapped the group as a solid candidate to have ended the year on a positive note and forecast stronger profit growth going forward, which led the analysts to raise their recommendation for the shares from 'neutral' to 'overweight'.
JPMorgan said the benefits of cost-cutting, organic growth of at least 2.5% and boosts from acquisitions throughout the year should help improve operating profit by around 25% between 2017 and 2019.
Spectris was forecast to post flat operating profits for the year, despite further revenue growth, but come twelve months later, JP Morgan estimated operating profits to move ahead no less than 14% and predicted operating profit growth of 12% in 2019.
The analysts said, "Over the past 18 months, Spectris has completed five acquisitions, the most significant of which were Millbrook and Concept Life Science which deliver testing services to the auto and pharma industries, respectively. We expect the annual number of new model launches by the auto industry in Europe to rise by almost 50% between 2017 and 2020."
"Overall, we expect this to trigger a re-rating of the group. With the shares trading at a discount to the sector and with 16% upside potential our revised Dec-18 price target of 2,900p (was 2,800p)," they concluded.
As of 1430 GMT, shares had grown 2.42% to 2,544.00p.
Related share prices |
---|
Spectris (SXS) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price